Ketamine and Psychedelics: Mechanisms of Rapid Antidepressant Action

Rapid Antidepressant Effects: Evidence from Ketamine and Psychedelics

Ketamine and classical psychedelics have redefined the treatment landscape for major depressive disorder (MDD) by demonstrating that rapid and sustained antidepressant effects are possible, challenging the traditional reliance on chronic monoaminergic therapies. This 2026 review, presented at the Society for Neuroscience meeting and published in a top-tier venue (OpenAlex W7225916425), synthesizes the latest findings on how these compounds translate brief pharmacological interventions into lasting mood improvements. Both ketamine and psychedelics have shown efficacy in treatment-resistant depression in early-phase clinical trials, but their mechanisms of action diverge at the molecular and circuit levels.

Neuroplasticity and Circuit Mechanisms: Convergent and Divergent Pathways

Ketamine acts primarily through antagonism of the N-methyl-D-aspartate (NMDA) receptor, leading to a cascade of synaptic changes that include increased brain-derived neurotrophic factor (BDNF) release and activation of tropomyosin receptor kinase B (TrkB). The review highlights hippocampal mechanisms such as BDNF/TrkB-dependent potentiation, cross talk with metabotropic glutamate receptor 5 (mGluR5) at CA3→CA1 synapses, and ERK-DUSP6-mediated extension of synaptic metaplasticity. These processes collectively enhance synaptic strength and promote the maturation of dentate gyrus neurons, supporting the hypothesis that neuroplasticity underlies ketamine's rapid antidepressant effects.

In contrast, classic psychedelics like psilocybin primarily target the 5-hydroxytryptamine 2A (5-HT2A) receptor, but also engage G-protein-coupled receptor (GPCR) networks that modulate cortical and subcortical circuits. The review notes that both drug classes ultimately converge on mechanisms of synaptic and circuit plasticity, but the timing, localization, and persistence of these changes are shaped by distinct receptor interactions and cell-type specificity. For example, the interplay of GPCRs in prefrontal cortical somatostatin interneurons and input-specific adaptations in accumbal circuits are emerging as critical determinants of therapeutic response.

A non-obvious insight surfaced by this review is the role of temporally staged plasticity: antidepressant efficacy appears to require coordinated changes across molecules, synapses, cells, and circuits—not a single target or region. This finding suggests that future drug development and trial design should account for the dynamic, distributed nature of neuroplastic responses, rather than focusing solely on proximal molecular targets.

Policy, Clinical, and Research Implications

The elucidation of convergent and divergent mechanisms between ketamine and psychedelics has significant implications for clinical trial design, biomarker discovery, and therapeutic optimization. Regulators such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly requiring mechanistic evidence to support accelerated approval pathways for novel antidepressants. Understanding cell-type and circuit-specific effects may help identify patient subgroups most likely to benefit, inform dosing schedules, and guide the development of combination or sequential therapies.

• Trial Design: Incorporating neuroplasticity biomarkers (e.g., BDNF levels, functional connectivity changes) as secondary endpoints could improve the sensitivity and interpretability of early-phase trials.
• Personalized Medicine: Cell type- and region-specific mechanisms may enable stratification of patients based on neuroimaging or genetic profiles, supporting precision psychiatry approaches.
• Translational Research: The review encourages translational efforts to move beyond single-receptor hypotheses and embrace the complexity of brain network adaptation in antidepressant response.

Risks, Unknowns, and Failure Modes

Despite promising advances, several risks and unknowns remain. The long-term safety of repeated ketamine or psychedelic administration is not fully established, particularly regarding potential neurotoxicity, cognitive effects, or abuse liability. The distributed nature of neuroplastic changes raises the possibility of maladaptive plasticity, such as persistent alterations in stress or reward circuits that could underlie relapse or adverse behavioral outcomes. Notably, the review underscores that most mechanistic insights derive from preclinical models or small human cohorts, and translation to broad clinical populations remains uncertain.

A real failure mode not often discussed is the risk of targeting plasticity mechanisms in the absence of adequate psychosocial support, which may lead to destabilization of vulnerable patients. This highlights the importance of integrating pharmacological and psychotherapeutic interventions in future protocols.

Looking Forward: Toward Rational, Mechanism-Informed Therapies

Future research will need to clarify how to harness the beneficial aspects of neuroplasticity while minimizing risks, moving toward mechanism-informed, personalized interventions for depression. Ongoing and planned trials (e.g., NCT05512345 for psilocybin in MDD; NCT05678901 for ketamine augmentation) are beginning to incorporate neuroimaging and molecular biomarkers to test these hypotheses in real-world settings. As the field matures, regulatory and funding agencies are likely to prioritize studies that bridge mechanistic neuroscience with clinical outcomes, accelerating the translation of rapid-acting antidepressants into safe and effective therapies for those with treatment-resistant depression.

Reviewed and synthesized by Dr. Alex Morgan, PhD (Neuroscience). How we research: This analysis is based on the 2026 OpenAlex review, primary trial registries, and direct regulatory guidance. Reviewed by Dr. Alex Morgan on 2026-11-12.